T-DXd Effective for Treating HER2+ Advanced or Metastatic Breast Cancer, Regardless of Treatment History, HR Status, or PIK3C Mutations - report from ESMO 2025

Medical Digest & Congress Report
14/11/2025 5 min

Listen "T-DXd Effective for Treating HER2+ Advanced or Metastatic Breast Cancer, Regardless of Treatment History, HR Status, or PIK3C Mutations - report from ESMO 2025"

Descargar episodio Ver en sitio original

Episode Synopsis

Professor Sibylle Loibl shares her thoughts on the additional analyses of DESTINY-Breast09 were presented at the ESMO Congress 2025. Key subgroup analysis of DESTINY-Breast09 confirms efficacy of trastuzumab deruxtecan plus pertuzumab for treating HER2+ advanced or metastatic breast cancer across groups. Video: https://medicaldigest.org/scientific-contents/interview:t-dxd-effective-treating-her2-advanced-or-metastatic-breast-cancer-regardless-treatment-history-hr-status-or-pik3c-mutations

More episodes of the podcast Medical Digest & Congress Report

Immuno-oncology biomarkers in locally advanced HNSCC - lessons from the KeyNote-689 trial - report from ESMO 2025 14/11/2025
Novelties of the treatment of colon cancer at ESMO 2025 14/11/2025
How to PROC - Breaking the Wall of Platinum-Resistance in Ovarian Cancer - report from ESMO 2025 14/11/2025
IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC - report from ESMO 2025 14/11/2025
What's new in ESMO guidelines? - report from ESMO 2025 14/11/2025
DYNAMIC-III trial results: ctDNA blood test is a powerful tool to guide treatment choices for people with advanced colon cancer - report from ESMO 2025 13/11/2025
Overcoming Therapeutic Challenges in High-risk Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Approach - report from ESMO 2025 13/11/2025
KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials - report from ESMO 2025 13/11/2025
Durvalumab in Combination with BCG for BCG-Naïve High-Risk NMIBC: Final Analysis of the Phase 3, Open-Label, Randomized POTOMAC Trial - report from ESMO 2025 13/11/2025
Treatment Landscape in Resectable LA HNSCC - report from ESMO 2025 13/11/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA